{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    46,
    47,
    48,
    49,
    51,
    52,
    61,
    62,
    64,
    65,
    66,
    67,
    68,
    69,
    70,
    71,
    93,
    101
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study drug",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "randomization date",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline assessment",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening \nvisit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_6",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_5",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_75",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "Daily \noral dosing"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until death"
      },
      {
        "id": "rep_cycle_4",
        "type": "Cycle",
        "cycleLength": "P6D",
        "exitCondition": "Disease progression",
        "sourceText": "Up to 6 cycles"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "treatment \nperiod"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "4 hours \nafter"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "4 hours after"
      },
      {
        "id": "rep_llm_1",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P90D",
        "interval": "P1D",
        "minObservations": 90,
        "exitCondition": "3 months after the last dose of study drug",
        "sourceText": "A sexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after the last dose of study drug."
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "radiographic disease progression is documented or starting an investigational agent or new therapy",
        "sourceText": "Study drug therapy should be continued as long as the subject is tolerating the study drug and continues ADT until radiographic disease progression is documented as outlined in the table below or starting an investigational agent or new therapy for treatment of prostate cancer."
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "discontinuation of study treatment",
        "sourceText": "Once randomized at day 1, subject must maintain ADT with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist during study treatment"
      },
      {
        "id": "rep_llm_4",
        "type": "Interval",
        "startOffset": "P13W",
        "interval": "P12W",
        "minObservations": 2,
        "exitCondition": "radiographic progression event is confirmed",
        "sourceText": "Subjects who discontinue study treatment without radiographic progression will continue to follow the radiographic assessment schedule until radiographic progression event is confirmed"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4",
          "epoch_5"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Screening",
          "Baseline",
          "Last Assessment After Completing Administration",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring discontinuation', 'path': ['DISCONTINUATION', 'FOLLOW_UP_OF_ADVERSE_EVENTS']}, {'condition': 'North America sites only', 'path': ['EXPLORATORY_OBJECTIVE_ASSESSMENT', 'OPTIONAL_BLOOD_SAMPLE_FOR_MUTATION_ANALYSIS']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "SINGLE signals: 10; RECURRING signals: 2"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Mri",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Screening is a one-time assessment to determine eligibility prior to randomization."
      },
      {
        "activityId": "Safety Monitoring",
        "executionType": "Single",
        "rationale": "Safety endpoints and assessments are scheduled to be repeated at study visits throughout the trial."
      },
      {
        "activityId": "Efficacy Assessments",
        "executionType": "Single",
        "rationale": "Primary and secondary endpoints are measured at scheduled intervals according to the Flow Chart and Schedule of Assessments."
      },
      {
        "activityId": "Treatment Code Breaking",
        "executionType": "Single",
        "rationale": "Unblinding is a conditional workflow triggered only by specific emergency or decision points."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "† Unscheduled visits may be performed at any time during the study whenever necessary to assess for or follow-up on adverse events at the subject’s request or if deemed necessary by the investigator.",
        "footnoteId": "fn_1",
        "structuredCondition": "event.unscheduled_visit == true IF (adverse_event_assessment == true OR subject_request == true OR investigator_discretion == true)",
        "appliesToActivityIds": [
          "Unscheduled visits"
        ],
        "sourceText": "† Unscheduled visits may be performed at any time during the study whenever necessary to assess for "
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "‡ After treatment discontinuation, all subjects MUST undergo long term follow-up. Long term follow-up assessments will include monitoring for survival status, new antineoplastic therapies for prostate cancer and symptomatic skeletal events.",
        "footnoteId": "fn_2",
        "structuredCondition": "phase.long_term_follow_up AFTER treatment_discontinuation == true",
        "appliesToActivityIds": [
          "Survival status monitoring",
          "New antineoplastic therapy monitoring",
          "Skeletal event monitoring"
        ],
        "sourceText": "‡ After treatment discontinuation, all subjects MUST undergo long term follow-up. Long term follow-u"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "§ Or prior to initiation of new antineoplastic therapy for prostate cancer, whichever occurs first.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.earliestOf(scheduled_visit, initiation_of_new_antineoplastic_therapy)",
        "appliesToActivityIds": [
          "Follow-up assessments"
        ],
        "sourceText": "§ Or prior to initiation of new antineoplastic therapy for prostate cancer, whichever occurs first."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_recurring",
        "text": "¶ A brief physical examination is required at each visit, with the exception of the screening visit during which a complete physical examination will be completed.",
        "footnoteId": "fn_4",
        "structuredCondition": "IF visit == 'Screening' THEN physical_exam.type = 'Complete' ELSE physical_exam.type = 'Brief'",
        "appliesToActivityIds": [
          "Physical examination"
        ],
        "sourceText": "¶ A brief physical examination is required at each visit, with the exception of the screening visit "
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "†† Laboratory assessments include serum chemistries and hematology.",
        "footnoteId": "fn_5",
        "structuredCondition": "laboratory_assessments.includes(serum_chemistries, hematology)",
        "appliesToActivityIds": [
          "Laboratory assessments"
        ],
        "sourceText": "†† Laboratory assessments include serum chemistries and hematology."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "‡‡ Genotyping samples will only be collected from subjects who agree to provide genotyping samples as documented by signing a separate genotyping informed consent form.",
        "footnoteId": "fn_6",
        "structuredCondition": "activity.perform IF subject_consent_genotyping == true",
        "appliesToActivityIds": [
          "Genotyping samples"
        ],
        "sourceText": "‡‡ Genotyping samples will only be collected from subjects who agree to provide genotyping samples a"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "∫∫ For sites in North America only: Blood samples for mutation analysis will be collected from subjects who agree to provide samples as documented by signing a separate genotyping informed consent form.",
        "footnoteId": "fn_7",
        "structuredCondition": "activity.perform IF (site_location == 'North America' AND subject_consent_genotyping == true)",
        "appliesToActivityIds": [
          "Blood samples for mutation analysis"
        ],
        "sourceText": "∫∫ For sites in North America only: Blood samples for mutation analysis will be collected from subje"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "§§ The abdominal-pelvic CT scan or MRI, bone scan, chest x-ray or chest CT must occur within 6 weeks of day 1; otherwise the screening visit assessment must be repeated.",
        "footnoteId": "fn_8",
        "structuredCondition": "IF timing.since(imaging_assessment) > P6W THEN screening_visit.repeat()",
        "appliesToActivityIds": [
          "Abdominal-pelvic CT scan",
          "MRI",
          "Bone scan",
          "Chest x-ray",
          "Chest CT"
        ],
        "sourceText": "§§ The abdominal-pelvic CT scan or MRI, bone scan, chest x-ray or chest CT must occur within 6 weeks"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "¶¶ The window for all radiological (CT/MRI) assessments is ± 7 days.",
        "footnoteId": "fn_9",
        "structuredCondition": "visit_window == P7D",
        "appliesToActivityIds": [
          "Radiological assessments",
          "CT",
          "MRI"
        ],
        "sourceText": "¶¶ The window for all radiological (CT/MRI) assessments is ± 7 days."
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "††† Chest CT/MRI is required at all imaging time points if screening chest x-ray demonstrates metastatic chest disease.",
        "footnoteId": "fn_10",
        "structuredCondition": "IF screening_chest_xray == 'metastatic_disease' THEN chest_imaging.required == true",
        "appliesToActivityIds": [
          "Chest CT",
          "Chest MRI"
        ],
        "sourceText": "††† Chest CT/MRI is required at all imaging time points if screening chest x-ray demonstrates metast"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_after",
        "text": "§§§ Adverse events will be collected from the time the subject signs the consent form until screen failure or through safety follow-up visit (30 days after last dose).",
        "footnoteId": "fn_11",
        "sourceText": "§§§ Adverse events will be collected from the time the subject signs the consent form until screen f"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "Tumor assessment",
          "RECIST criteria"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "Duration of study treatment"
        },
        "algorithm": "subjects with (Complete Response + Partial Response) / total subjects in analysis set",
        "successCriteria": "Confirmed CR or PR per RECIST",
        "sourceText": "ORR Objective response rate"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of death",
          "Date of randomization"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death or study end"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Time from randomization to death from any cause",
        "sourceText": "OS Overall survival"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Volume of Disease",
        "variableType": "Categorical",
        "sourceVariables": [
          "Visceral metastases",
          "Bone lesions count",
          "Bone lesion location"
        ],
        "derivationRule": "If metastases involve viscera OR (if no visceral lesions, count >= 4 bone lesions AND at least 1 lesion is beyond vertebral column/pelvic bone) then 'High Volume'; else 'Low Volume'",
        "baselineDefinition": "Assessment at time of randomization",
        "baselineVisit": "Screening/Baseline",
        "analysisWindow": "Prior to randomization",
        "imputationRule": "None specified",
        "unit": "n/a"
      },
      {
        "id": "dv_2",
        "name": "Prior Docetaxel Therapy",
        "variableType": "Categorical",
        "sourceVariables": [
          "Docetaxel cycle count"
        ],
        "derivationRule": "Categorized as: No prior docetaxel, 1-5 cycles, or 6 cycles. Prior therapy defined as 1 or more cycles but no more than 6.",
        "baselineDefinition": "Medical history prior to randomization",
        "baselineVisit": "Screening",
        "analysisWindow": "Prior to randomization",
        "imputationRule": "None specified",
        "unit": "cycles"
      },
      {
        "id": "dv_3",
        "name": "Radiographic Disease Progression",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "CT scan",
          "MRI scan",
          "Bone scan"
        ],
        "derivationRule": "Time from randomization to documented radiographic progression as confirmed by independent central imaging review.",
        "baselineDefinition": "First dose or randomization date",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until radiographic progression or target events reached",
        "imputationRule": "Censoring rules apply for subjects without progression (details in section 7.10)",
        "unit": "days/months"
      },
      {
        "id": "dv_4",
        "name": "Overall Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Death",
          "Date of Randomization"
        ],
        "derivationRule": "Time from randomization to death from any cause.",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until death or study completion",
        "imputationRule": "Censored at last date known alive",
        "unit": "days/months"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Double-blind Treatment Period",
        "Safety Follow-up",
        "Unscheduled",
        "Long Term Follow-up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Double-blind Treatment Period",
          "trigger": "Progress to Double-blind Treatment Period"
        },
        {
          "fromState": "Double-blind Treatment Period",
          "toState": "Safety Follow-up",
          "trigger": "Progress to Safety Follow-up"
        },
        {
          "fromState": "Safety Follow-up",
          "toState": "Unscheduled",
          "trigger": "Progress to Unscheduled"
        },
        {
          "fromState": "Unscheduled",
          "toState": "Long Term Follow-up",
          "trigger": "Progress to Long Term Follow-up"
        },
        {
          "fromState": "Double-blind Treatment Period",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "epoch_1",
        "Double-blind Treatment Period": "epoch_2",
        "Safety Follow-up": "epoch_3",
        "Unscheduled": "epoch_4",
        "Long Term Follow-up": "epoch_5",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Enzalutamide",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 40.0,
            "unit": "mg"
          },
          {
            "amount": 160.0,
            "unit": "mg"
          }
        ],
        "doseModifications": [
          "Dose modifications may occur based on Section 5.1.2 'Increase or Reduction in Dose of the Study Drug(s)'"
        ],
        "sourceText": "dy capsule components, including Labrasol®, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT). Waivers to the exclusion criteria will NOT be allowed. Investigational Product(s): Enzal"
      },
      {
        "id": "dosing_2",
        "treatmentName": "AUC24h",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 322.0,
            "unit": "μg"
          },
          {
            "amount": 317.0,
            "unit": "μg"
          }
        ],
        "durationDescription": "2 years",
        "sourceText": "d not show carcinogenic potential (absence of neoplastic findings) at doses up to 20 mg/kg per day (AUC24h ≈317 μg∙h/mL), which resulted in plasma exposure levels similar to the clinical exposure (AUC"
      },
      {
        "id": "dosing_3",
        "treatmentName": "Nonsubstantial Amendment",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "g"
          }
        ],
        "sourceText": "vant systemic concentrations or in the Sponsor: APGD ISN/Protocol 9785-CL-0335 EudraCT number 2015-003869-28 - CONFIDENTIAL - 18 Apr 2022 Astellas Page 35 of 106 Version 5.1 Incorporating Nonsubstanti"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1
      }
    ],
    "visitWindows": [
      {
        "id": "visit_5",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Screening A process of active consideration of potential subjects for enrollment in a trial. Study period"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Adverse Events and Other Safety Aspects ················································· 56 5.5.1 Definition of Adverse Events ·························································· 56"
      },
      {
        "id": "visit_3",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "Demographics and Other Baseline Characteristics ········································ 66 7.4 Analysis of Efficacy ·········································································· 66"
      },
      {
        "id": "visit_8",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "MRI by RECIST v1.1 No confirmatory scan required for soft tissue"
      },
      {
        "id": "visit_9",
        "visitName": "Visit 30",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "Subjects will have a safety follow-up visit 30 days after their last dose of study drug or prior to initiation of another investigational agent or new therapy for prostate cancer, whichever occurs fir"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 3100",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "(FACT-P). Study MDV3100-03 (PREVAIL) showed a significant benefit of enzalutamide in time to initiation of cytotoxic chemotherapy. Study MDV3100-03 (PREVAIL; chemotherapy naïve mCRPC subjects) was sto"
      },
      {
        "id": "visit_4",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "where the test drug or comparative drug (sometimes without randomization) is usually given to a subject, and continues until the last assessment after completing administration of the test drug or com"
      },
      {
        "id": "visit_10",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Once randomized at day 1, subject must maintain ADT with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., m"
      },
      {
        "id": "visit_12",
        "visitName": "Day 14",
        "targetDay": 14,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "day 14, enzalutamide and/or its metabolites were present in the fetus at a Cmax that was approximately 0.3 times the concentration found in maternal plasma and occurred 4 hours after administration (s"
      },
      {
        "id": "visit_13",
        "visitName": "Day 28",
        "targetDay": 28,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "5.8 days. Enzalutamide steady state was achieved by day 28, and the accumulation ratio was 8.3-fold. At steady state, enzalutamide showed approximately dose-proportional pharmacokinetics over the rang"
      },
      {
        "id": "visit_6",
        "visitName": "Week 13",
        "targetDay": 85,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 13,
        "sourceText": "Week 13 Bone lesions: ≥ 2 new lesions compared to baseline"
      },
      {
        "id": "visit_15",
        "visitName": "Day 85",
        "targetDay": 85,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "repeated at day 85/week 13 visit and every 12 weeks thereafter. Imaging may be performed at any time to confirm suspected disease progression. Assessment will include tumor"
      },
      {
        "id": "visit_7",
        "visitName": "Week 25",
        "targetDay": 169,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "targetWeek": 25,
        "sourceText": "week 25 visit ≥ 2 new bone lesions on bone scan compared to week 13 scan (≥ 4"
      },
      {
        "id": "visit_11",
        "visitName": "Week 49",
        "targetDay": 337,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 49,
        "sourceText": "genotyping informed consent form. Samples will be collected at randomization, at week 49 and at study treatment discontinuation. §§ The abdominal-pelvic CT scan or MRI, bone scan, chest x-ray or chest"
      },
      {
        "id": "visit_2",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "Follow-up of Adverse Events ·························································· 60 5.5.7 Monitoring of Common Serious Adverse Events ··································· 60"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Volume of disease",
          "categories": [
            "low",
            "high"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior docetaxel therapy for prostate cancer",
          "categories": [
            "no prior docetaxel",
            "1-5 cycles",
            "6 cycles"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Sponsor: APGD \nISN/Protocol 9785-CL-0335 \nEudraCT number 2015-003869-28 \n \n- CONFIDENTIAL - \n18 Apr 2022 \nAstellas \nPage 12 of 106 \nVersion 5.1 Incorporating Nonsubstantial Amendment 6 \nAbbreviations "
    }
  }
}